Last reviewed · How we verify

Ramipril (ACE-inhibitor) — Competitive Intelligence Brief

Ramipril (ACE-inhibitor) (Ramipril (ACE-inhibitor)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACE inhibitor. Area: Cardiovascular.

marketed ACE inhibitor Angiotensin-converting enzyme (ACE) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Ramipril (ACE-inhibitor) (Ramipril (ACE-inhibitor)) — National Heart Institute, Egypt. Ramipril inhibits angiotensin-converting enzyme (ACE), reducing the conversion of angiotensin I to angiotensin II and thereby lowering blood pressure and reducing cardiac workload.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ramipril (ACE-inhibitor) TARGET Ramipril (ACE-inhibitor) National Heart Institute, Egypt marketed ACE inhibitor Angiotensin-converting enzyme (ACE)
Vasotec enalapril Merck & Co. marketed ACE inhibitor Angiotensin-converting enzyme, Angiotensin-converting enzyme 1985-12-24
Calcium Channel Blockers, ACE-Inhibitor Calcium Channel Blockers, ACE-Inhibitor University of Aarhus marketed Combination antihypertensive (calcium channel blocker + ACE inhibitor) L-type calcium channels; Angiotensin-converting enzyme (ACE)
ACE Inhibitors and Diuretics ACE Inhibitors and Diuretics The University of Texas Health Science Center, Houston marketed ACE inhibitor + diuretic combination Angiotensin-converting enzyme (ACE); various diuretic targets depending on class (e.g., loop of Henle, distal convoluted tubule)
captopril, Losartan (drug) captopril, Losartan (drug) National Taiwan University Hospital marketed ACE inhibitor and angiotensin II receptor antagonist combination ACE enzyme and AT1 receptor
RASi plus carvedilol RASi plus carvedilol Federal University of Minas Gerais marketed ACE inhibitor or ARB combined with non-selective beta-blocker Angiotensin II receptor / ACE enzyme; beta-1 and beta-2 adrenergic receptors; alpha-1 adrenergic receptor
Perindopril + amlodipine + if necessary, hydrochlorothiazide Perindopril + amlodipine + if necessary, hydrochlorothiazide Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company marketed ACE inhibitor + calcium channel blocker + thiazide diuretic combination Angiotensin-converting enzyme (ACE), L-type calcium channels, sodium-chloride cotransporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACE inhibitor class)

  1. Boryung Pharmaceutical Co., Ltd · 5 drugs in this class
  2. Bioprojet · 2 drugs in this class
  3. Ain Shams University · 2 drugs in this class
  4. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 drug in this class
  5. Beijing Tide Pharmaceutical Co., Ltd · 1 drug in this class
  6. Children's Hospital of Fudan University · 1 drug in this class
  7. Ache Laboratorios Farmaceuticos S.A. · 1 drug in this class
  8. Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
  9. Ethicare GmbH · 1 drug in this class
  10. Ace Cells Lab Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ramipril (ACE-inhibitor) — Competitive Intelligence Brief. https://druglandscape.com/ci/ramipril-ace-inhibitor. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: